Apontis Pharma AG (XETRA:APPH) — Market Cap & Net Worth
Market Cap & Net Worth: Apontis Pharma AG (APPH)
Apontis Pharma AG (XETRA:APPH) has a market capitalization of $91.63 Million (€78.38 Million) as of September 19, 2026. Listed on the XETRA stock exchange, this Germany-based company holds position #19606 globally and #1792 in its home market, demonstrating a 2.33% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Apontis Pharma AG's stock price €11.00 by its total outstanding shares 8330000 (8.33 Million). Also see Apontis Pharma AG balance sheet assets for a full breakdown of the balance sheet.
Apontis Pharma AG Market Cap History: 2021 to 2025
Apontis Pharma AG's market capitalization history from 2021 to 2025. Data shows change from $194.77 Million to $107.13 Million (-11.14% CAGR). Also see cash efficiency ratio of Apontis Pharma AG for how efficiently the company converts equity into cash flow.
Apontis Pharma AG Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Apontis Pharma AG's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Apontis Pharma AG share price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
2.02x
Apontis Pharma AG's market cap is 2.02 times its annual revenue
Latest Price to Earnings (P/E) Ratio
129.88x
Apontis Pharma AG's market cap is 129.88 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $194.77 Million | $51.18 Million | -$745.24K | 3.81x | N/A |
| 2022 | $79.86 Million | $55.73 Million | $2.69 Million | 1.43x | 29.70x |
| 2023 | $46.26 Million | $36.96 Million | -$11.30 Million | 1.25x | N/A |
| 2024 | $97.87 Million | $48.47 Million | $753.57K | 2.02x | 129.88x |
Competitor Companies of APPH by Market Capitalization
Companies near Apontis Pharma AG in the global market cap rankings as of September 19, 2026. Review Apontis Pharma AG tangible equity quality to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Apontis Pharma AG by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #520 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #619 globally with a market cap of $44.48 Billion USD.
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #637 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
- Haleon plc (NYSE:HLN): Ranked #665 globally with a market cap of $41.22 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #520 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #619 | GALDERMA GROUP AG | NYSE:GALDY | $44.48 Billion | $38.15 |
| #637 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €16.10 |
| #665 | Haleon plc | NYSE:HLN | $41.22 Billion | $9.36 |
Apontis Pharma AG Historical Marketcap From 2021 to 2025
Between 2021 and today, Apontis Pharma AG's market cap moved from $194.77 Million to $ 107.13 Million, with a yearly change of -11.14%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | €107.13 Million | +9.45% |
| 2024 | €97.87 Million | +111.58% |
| 2023 | €46.26 Million | -42.07% |
| 2022 | €79.86 Million | -59.00% |
| 2021 | €194.77 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 18th, 2026 the market cap of Apontis Pharma AG was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $91.63 Million USD |
| MoneyControl | $91.63 Million USD |
| MarketWatch | $91.63 Million USD |
| marketcap.company | $91.63 Million USD |
| Reuters | $91.63 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Apontis Pharma AG
Apontis Pharma AG markets and sells medical drugs for indication fields of internal medicine in Germany. It offers single pills and other pharmaceutical products with a focus on cardiovascular diseases, such as hypertension, dylipidemia, secondary prophylaxis, and asthma, as well as respiratory diseases and diabetes. The company was founded in 1946 and is based in Monheim am Rhein, Germany. Apont… Read more